Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 27, 2023

SELL
$9.86 - $23.83 $61,940 - $149,700
-6,282 Reduced 2.87%
212,864 $0
Q3 2022

Nov 01, 2022

SELL
$21.04 - $36.06 $1.13 Million - $1.94 Million
-53,887 Reduced 19.74%
219,146 $4.91 Million
Q2 2022

Aug 08, 2022

BUY
$17.78 - $42.39 $482,140 - $1.15 Million
27,117 Added 11.03%
273,033 $6.77 Million
Q1 2022

May 05, 2022

SELL
$29.67 - $60.28 $127,462 - $258,962
-4,296 Reduced 1.72%
245,916 $9.53 Million
Q4 2021

Feb 14, 2022

SELL
$47.84 - $64.34 $504,424 - $678,400
-10,544 Reduced 4.04%
250,212 $14.6 Million
Q3 2021

Nov 09, 2021

SELL
$59.27 - $95.73 $4.43 Million - $7.15 Million
-74,671 Reduced 22.26%
260,756 $15.5 Million
Q2 2021

Jul 29, 2021

SELL
$67.25 - $92.52 $3.29 Million - $4.53 Million
-48,935 Reduced 12.73%
335,427 $29.1 Million
Q1 2021

May 14, 2021

SELL
$72.16 - $117.4 $213,954 - $348,091
-2,965 Reduced 0.77%
384,362 $31.7 Million
Q4 2020

Feb 16, 2021

BUY
$38.09 - $100.95 $2.3 Million - $6.11 Million
60,483 Added 18.51%
387,327 $35.2 Million
Q3 2020

Nov 16, 2020

BUY
$30.41 - $40.5 $9.94 Million - $13.2 Million
326,844 New
326,844 $13.1 Million

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $99.9M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Rice Hall James & Associates, LLC Portfolio

Follow Rice Hall James & Associates, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rice Hall James & Associates, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rice Hall James & Associates, LLC with notifications on news.